<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04059289</url>
  </required_header>
  <id_info>
    <org_study_id>JJ-EY-AA_1</org_study_id>
    <nct_id>NCT04059289</nct_id>
  </id_info>
  <brief_title>Intermediate Vision in a Driving Simulator Environment: Comparison of the J&amp;J EYHANCE With a Conventional Monofoc. IOL</brief_title>
  <acronym>JJ-EYHANCE</acronym>
  <official_title>Intermediate Vision in a Driving Simulator Environment: Comparison of the New J&amp;J EYHANCE IOL With a Conventional Monofocal IOL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aalen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at
      intermediate distances under nighttime driving conditions in a driving simulator between
      patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual
      function testing in the driving simulator will be assessed without AND with (static) glare.

      Additionally: Assessment of individual response times, scanpath characteristics, evaluation
      of test retest reliability and self-evaluation of (intermediate) vision and visual impairment
      related to glare.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare (low contrast) visual acuity (VA) and contrast sensitivity (CS) - both at
      intermediate distances under nighttime driving conditions in a driving simulator between
      patients with bilateral EYHANCE IOLs OR bilateral conventional monofocal IOLs. Visual
      function testing in the driving simulator will be assessed without AND with (static) glare.

      Additionally: Assessment of individual response times, scanpath characteristics, evaluation
      of test retest reliability and self-evaluation of (intermediate) vision and visual impairment
      related to glare.

      Simulator

      Patients are instructed to drive with a constant speed of 40 km/h on a virtual parcours
      (straight lane). For testing of either (low contrast) visual acuity or contrast sensitivity,
      8-position LANDOLT C's are presented at three locations (within the simulator car, AUDI A4,
      Ingolstadt/FRG):

      (i) At the center of the instrument panel (distance 0.xx m) (ii) At the center of the
      navigation monitor (y.yy m) (iii) At the center of the rear monitor (z.zz m) A high
      resolution acoustic attention guidance for immediate gaze direction of the patients towards
      the three above-mentioned visual stimulus locations (i-iii) is mandatory.

      Patients responses are recorded and response times can be extracted from the recordings.

      Clinical ophthalmological-optical examinations

        -  Medical/ophthalmological history

        -  (Uncorrected and Best-corrected) visual acuity (RE,LE,BE) with remote and intermediate
           (66cm) 8 position LANDOLT C's.

        -  LANG I stereotest (near distance)

        -  Ocular alignment &amp; ocular motility

        -  Efferent &amp; afferent pupillomotor status

        -  Mesopic contrast sensitivity without/with glare (Optovist, VISTEC Inc./Olching/FRG)

        -  Intraocular straylight perception (Q-Quant, OCULUS Inc, Wetzlar/FRG)

        -  Slit lamp (anterior segment)

        -  Ophthalmoscope (central fundus and fixation)

             -  Primary objectives: log visual acuity (logVA) at preset low contrast level of 1:2.7
                (logCS = 0.2) AND log contrast sensitivity (logCS) at a preset visual acuity level
                of 0.1 = 2/20)

             -  Secondary objectives: test retest reliability (as operationalized by LOA = limits
                of agreement) AND response time (i.e. time interval between onset of stimulus
                presentation and final response) AND scanpath characteristics (fixation duration,
                fixation stability, annotation to regions of interest; saccade amplitude)
                self-evaluation (questionnaire, using visual analogue scales = VAS)

      SHAPIRO WILK test (statistical testing for proving/disproving normal distribution)
      Descriptive statistics (either MEAN, standard deviation, in case of normally distributed data
      - else, MEDIAN, inter-quartile range (IQR).

      Assessment of test/retest reliability: BLAND ALTMAN plots, limits of agreement (LOA)
      Between-group comparison: t-test (unpaired samples), in case of normally distributed data -
      else, WILCOXON signed-rank test
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2020</start_date>
  <completion_date type="Actual">March 15, 2020</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>logVA</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>logarithm of visual acuity at preset low contrast level of 1:2.7 (logCS = 0.2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>logCS</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>logarithm of contrast sensitivity at a preset visual acuity level of 0.1 (= 2/20)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibilities of logVA</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>as operationalized by LOA (limits of agreement)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resonse times of logCS</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>time interval between onset of stimulus presentation amd final response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scanpath characteristics (I)</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>fixation duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scanpath characteristics (II)</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>fixation stability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scanpath characteristics (III)</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>annotation to regions of interest (ROIs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scanpath characteristics (IV)</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>saccade amplitude</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-evaluation (questionnaire) (i) distant vision with best distant correction</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>Distant vision (self-eval., vis. analogue scales: 0 = unsatisfactory ... 10 = optimal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-evaluation (questionnaire) (i) intermediate vision with best distant correction</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>Intermed. vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-evaluation (questionnaire) (i) mesopic vision with best distant correction</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>Mesopic vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-evaluation (questionnaire) (i) glare sensitivity with best distant correction</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>Glare sensitivity (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-evaluation (questionnaire) (i) General post-op vision with best distant corr.</measure>
    <time_frame>at least two months after uneventful intraocular lens implantation</time_frame>
    <description>Post-op vision (self-eval., vis. analog. scales: 0 = unsatisfactory ... 10 = optimal)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Lenses, Intraocular</condition>
  <condition>Pseudophakia</condition>
  <condition>Near Vision</condition>
  <condition>Driving</condition>
  <arm_group>
    <arm_group_label>Intraocular lens type I</arm_group_label>
    <description>Tecnis EYHANCE IOL (Johnson &amp; Johnson, New Brunswick/USA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intraocular lens type II</arm_group_label>
    <description>Clareon IOL (Alcon Pharma. Freiburg/FRG)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Posterior chamber intraocular lens (IOL)</intervention_name>
    <description>This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study</description>
    <arm_group_label>Intraocular lens type I</arm_group_label>
    <arm_group_label>Intraocular lens type II</arm_group_label>
    <other_name>Tecnis EYHANCE IOL (Johnson &amp; Johnson, New Brunswick/USA)</other_name>
    <other_name>Clareon IOL (Alcon Pharma. Freiburg/FRG)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two types of intraocular lenses
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of male or femal gender above the age of 18 years at least two months post surgery
        after bilateral uneventful IOL surgery (bilateral implantation of either EYHANCE IOL OR
        monofocal IOL)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  S.p. (at least two months post surgery) bilateral uneventful IOL surgery (bilateral
             implantation of either EYHANCE IOL OR monofocal IOL)

          -  Ophthalmological history normal, except cataract and uneventful IOL surgery

          -  Distant visual high-contrast acuity &gt; 20/25 in either eye

          -  Normal stereopsis (all figures of the LANG I random dot stereo test correctly
             recognized)

        Exclusion Criteria:

          -  Age below 18 years

          -  Chronic eye disease (except cataract)

          -  History of ocular surgery (except complication-free IOL surgery)

          -  Visual pathway lesions

          -  Strabismus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Applied Sciences, Study Course Ophthalmic Optics</name>
      <address>
        <city>Aalen</city>
        <state>Baden-WÃ¼rttemberg</state>
        <zip>73430</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2019</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glare</keyword>
  <keyword>contrast sensitivity</keyword>
  <keyword>driving simulator</keyword>
  <keyword>intermediate visual acuity</keyword>
  <keyword>pseudophakia</keyword>
  <keyword>posterior chamber intraocular lenses</keyword>
  <keyword>benchmark</keyword>
  <keyword>straylight</keyword>
  <keyword>nighttime driving</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudophakia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

